SpeeDx Pty Ltd

SpeeDx Pty Ltd is an Australian molecular diagnostics company specializing in multiplex PCR assays and proprietary technologies for detecting viral and bacterial infections, including antibiotic resistance markers. Founded in 2009 and headquartered in Sydney, the company develops PlexZyme®, PlexPrime®, and PlexPlus® multiplexing technologies that enable simultaneous detection of multiple diagnostic targets with high sensitivity and specificity. SpeeDx serves reference laboratories, diagnostic companies, instrument manufacturers, pharma, and biotech organizations globally. The company offers three core product lines: multiplexed IVD products for clinical diagnostics (sexually transmitted infections, respiratory, enteric panels), targeted research assays for infectious disease research, and custom development solutions. Beyond products, SpeeDx provides comprehensive partnering services including technology licensing, bespoke assay development, regulatory strategy, and manufacturing scale-up support. The company's multiplexing platform can achieve up to 12+ targets per well with unparalleled specificity for mutation differentiation, significantly reducing testing costs and time-to-result while improving laboratory efficiency across major molecular platforms.